Onkologische Behandlungsmöglichkeiten von Nieren- und Nierenbeckentumoren

Ehrhart, H

doi:10.1007/978-3-642-80933-0_42

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occasionally witnessed benefit from progestin therapy in patients suf fering from advanced renal cell carcinoma, in conjunction with the well-known resistance o f this tumour to radiotherapy (6,11,13) and various chemothera peutic manoeuvres (6,11), has led to the continued use o f progestational compounds in the treatment of this relentless disease.…”

Section: Introductionmentioning

confidence: 99%

The Endocrine Background of Human Renal Cell Carcinoma

1979

View full text Add to dashboard Cite

Cytosol preparations obtained from 9 different human renal cell carcinomas were investigated for the eventual presence of progestin-binding inhibitors which might offer an explanation for the previous failure to demonstrate high receptor levels in the tumour tissue. The inhibitory potency of these preparations was estimated by measuring the decrease of R 5020 binding to uterine progestin receptors in the presence of tumour cytosol. Interestingly, cytosol from human renal cell carcinoma was found to contain progestin-binding inhibitors. The average inhibition of R-5020-receptor interaction amounted to 46%. In only 1 out of 9 cases, binding was completely suppressed. In order to circumvent the inhibitory reaction potentially occurring in cell-free systems, R-5020-binding studies additionally were performed in cell suspension. Out of 7 carcinomas studied using this assay system, 5 did not contain any specific progestin-binding entities. In 1 tumour, receptor-atypical non-saturable binding was observed. Only in isolated cells prepared from 1 other carcinoma, could slight indications for the presence of low concentrations of progestin receptors be detected.

show abstract

Section: Introductionmentioning

confidence: 99%

The Endocrine Background of Human Renal Cell Carcinoma

1979

View full text Add to dashboard Cite

show abstract

“…Human renal cell carcinoma is known to be resistant to radiotherapy as well as single and multiple-agent chemotherapy (9,10,17,18). In this situation, hormonal treatment with progestational compounds, as for example medroxy progesterone acetate, has widely been used in the management of the dissemiDcdicated to Prof. Dr. S. Holtmann on the occasion of his 65th birthday.…”

Section: Introductionmentioning

confidence: 99%

The Endocrine Background of Human Renal Cell Carcinoma

1979

View full text Add to dashboard Cite

In order to investigate whether progestins may trigger tumour regression by a mechanism involving the glucocorticoid receptor, human renal cell carcinomas obtained from 15 patients were analysed for cytoplasmic glucocorticoid-binding components, using [³H] dexamethasone. The existence of glucocorticoid binders could be demonstrated in 10 out of 15 tumours studied. The average binding capacity was calculated and found to be 7.1 fmol/mg of cytosol protein. The apparent dissociation constant determined in the cell-free system amounted to 1.9 × 10^––8 mol/l. The ligand specificity experiments clearly indicated that binding to these receptors is not restricted to glucocorticoids alone. Progesterone and aldosterone turned out to be moderate competitors for dexamethasone binding. Medroxyprogesterone acetate, the compound widely used in hormone therapy of advanced renal cancer in man, was demonstrated to be one of the strongest inhibitors of [³H] dexamethasone. It is concluded that binding of medroxyprogesterone acetate to glucocorticoid receptors might represent the primary mechanism of action of the compound in causing tumour regression.

show abstract

Onkologische Behandlungsmöglichkeiten von Nieren- und Nierenbeckentumoren

Cited by 2 publications

References 0 publications

The Endocrine Background of Human Renal Cell Carcinoma

The Endocrine Background of Human Renal Cell Carcinoma

The Endocrine Background of Human Renal Cell Carcinoma

Contact Info

Product

Resources

About